GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » Enterprise Value

Innate Pharma (Innate Pharma) Enterprise Value : $142.61 Mil (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Innate Pharma's Enterprise Value is $142.61 Mil. Innate Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.58 Mil. Therefore, Innate Pharma's EV-to-EBIT ratio for today is -18.82.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Innate Pharma's Enterprise Value is $142.61 Mil. Innate Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.05 Mil. Therefore, Innate Pharma's EV-to-EBITDA ratio for today is -69.56.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Innate Pharma's Enterprise Value is $142.61 Mil. Innate Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $56.35 Mil. Therefore, Innate Pharma's EV-to-Revenue ratio for today is 2.53.


Innate Pharma Enterprise Value Historical Data

The historical data trend for Innate Pharma's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Enterprise Value Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 285.17 161.80 277.31 233.95 169.04

Innate Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 277.31 130.79 233.95 195.28 169.04

Competitive Comparison of Innate Pharma's Enterprise Value

For the Biotechnology subindustry, Innate Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innate Pharma's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Enterprise Value falls into.



Innate Pharma Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Innate Pharma's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Innate Pharma's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innate Pharma  (NAS:IPHA) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Innate Pharma's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=142.606/-7.576
=-18.82

Innate Pharma's current Enterprise Value is $142.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.58 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Innate Pharma's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=142.606/-2.05
=-69.56

Innate Pharma's current Enterprise Value is $142.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.05 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Innate Pharma's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=142.606/56.349
=2.53

Innate Pharma's current Enterprise Value is $142.61 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $56.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innate Pharma Enterprise Value Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Innate Pharma (Innate Pharma) Business Description

Traded in Other Exchanges
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.